Use of Lactobacillus probiotics for bacterial genitourinary infections in women: A review

Clinical Therapeutics

Volumn 30, Issue 3, 2008, Pages 453-468

  Barrons, Robert ^a   Tassone, Dan ^b  

^a WINGATE UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

bacterial vaginosis; Lactobacillus; probiotics; urinary tract infection; vaginal colonization; vaginal flora

Indexed keywords

CEFAZOLIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLINDAMYCIN; COTRIMOXAZOLE; CRANBERRY EXTRACT; ESTROGEN; METRONIDAZOLE; NITROFURANTOIN; NORFLOXACIN; PLACEBO; PROBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPERMICIDAL AGENT; VANCOMYCIN;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTEREMIA; BACTERIAL COLONIZATION; BACTERIAL INFECTION; CANDIDIASIS; CLINICAL TRIAL; COCHRANE LIBRARY; COMMENSAL; ENDOCARDITIS; FRUIT JUICE; FUNGEMIA; HUMAN; INFECTION; INFECTION PREVENTION; LACTOBACILLUS; LINGONBERRY; MEDLINE; PATIENT COMPLIANCE; UROGENITAL TRACT INFECTION; VAGINA FLORA;

FEMALE; FEMALE UROGENITAL DISEASES; HUMANS; LACTOBACILLUS; PROBIOTICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; URINARY TRACT INFECTIONS; VAGINOSIS, BACTERIAL;

EID: 41849150786     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.03.013     Document Type: Article

References (45)

1. Report of a Joint FAO/WHO Expert Consultation on health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. American Córdoba Park Hotel, Córdoba, Argentina, 1-4 October 2001 (2008). http://www.who.int/foodsafety/publications_fs_management/en/probiotics.p df Accessed February 11
2. Parkes GC. An overview of probiotics and prebiotics. Nurs Stand 21 (2007) 43-47
3. Ross J., Boucher P., Bhattacharyya S., et al. Considerations in the development of live biotherapeutic produts for clinical use. Curr Issues Mol Biol 10 (2008) 13-16. http://www.horizonpress.com/cimb/v/v10/02.pdf Accessed February 28
4. Forsum U., Holst E., Larsson P., et al. Bacterial vaginosis-a microbiological and immunological enigma. APMIS 113 (2005) 81-90
5. Sweet R. Gynnecologic conditions and bacterial vaginosis: Implications for the non-pregnant patient. Infect Dis Obstet Gynecol 8 (2000) 184-190
6. Felis G., and Dellaglio F. Taxonomy of Lactobacilli and Bifidobacteria. Curr Issues Intest Microbiol 8 (2007) 44-61
7. McLean N., and Rosenstein I. Characterization and selection of a Lactobacillus species to recolonise the vagina of women with recurrent bacterial vaginosis. J Med Microbiol 49 (2000) 543-552
8. Morelli L., Zonenenschain D., Del Piano M., and Cognein P. Utilization of the intestinal tract as a delivery system for urogenital probiotics. J Clin Gastroenterol 38 (2004) S107-S110
9. Mastromarino P., Brigidi P., Macchia S., et al. Characterization and selection of vaginal Lactobacillus strains for the preparation of vaginal tablets. J Appl Microbiol 93 (2002) 884-893
10. Reid G., and Burton J. Use of Lactobacillus to prevent infection by pathogenic bacteria. Microbes Infec. 4 (2002) 319-324
11. Reid G., Charbonneau D., Erb J., et al. Oral use of Lactobacillus rhamnosus GR-1 and Lfermentum RC-14 significantly alters vaginal flora: Randomized, placebo-controlled trial in 64 healthy women. FEMS Immunol Med Microbiol 35 (2003) 131-134
12. Cadieux P., Burton J., Gardiner G., et al. Lactobacillus strains and vaginal ecology. JAMA 287 (2002) 1940-1941
13. Gardiner G., Heinemann C., Bruce A., et al. Persistence of Lactobacillus fermentum RC-14 and Lactobacillus rhamnosus GR-1 but not L. rhamnosus GG in the human vagina as demonstrated by randomly amplified polymorphic DNA. Clin Diagn Lab Immunol 9 (2002) 92-96
14. Reid G., Beuerman D., Heinemann C., and Bruce A. Probiotic Lactobacillus dose required to restore and maintain a normal vaginal flora. FEMS Immunol Med Microbiol 32 (2001) 37-41
15. Aroutcheva A., Gariti D., Simon M., et al. Defense factors of vaginal Lactobacilli. Am J Obstet Gynecol 185 (2001) 375-379
16. Velraeds M., van der Mei H., and Reid G. Inhibition of initial adhesion of uropathogen Enterococcus faecalis by biosurfactants from Lactobacillus isolates. Appl Environ Microbiol 62 (1996) 1958-1963
17. Wilson J. Managing recurrent bacterial vaginosis. Sex Transm Infect 80 (2004) 8-11
18. Forsum U., Hallén A., and Larsson P. Bacterial vaginosis-a laboratory and clinical diagnostics enigma. APMIS 113 (2005) 153-161
19. Centers for Disease Control and Prevention; Sexually transmitted diseases treatment guidelines 2002. MMWR Recomm Rep 51 RR-6 (2002) 1-78
20. US Dept of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: Bacterial vaginosis-developing antimicrobial drugs for treatment (2008). http://www.fda.gov/cder/guidance/2572dft.pdf Accessed February 15
21. Larsson P., and Forsum U. Bacterial vaginosis-a disturbed bacterial flora and treatment enigma. APMIS 113 (2005) 305-316
22. Austin M., Beigi R., Meyn L., and Hillier S. Microbiologic response to treatment of bacterial vaginosis with topical clindamycin or metronidazole. J Clin Microbiol 43 (2005) 4492-4497
23. Anukam K., Osazuwa E., Ahonkhai I., et al. Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: Randomized, double-blind, placebo controlled trial. Microbes Infect 8 (2006) 1450-1454
24. Shalev E., Battino S., Weiner E., et al. Ingestion of yogurt containing Lactobacillus acidophilus compared with pasteurized yogurt as prophylaxis for recurrent candidal vaginitis and bacterial vaginosis. Arch Fam Med 5 (1996) 593-596
25. Neri A., Sabah G., and Samra Z. Bacterial vaginosis in pregnancy treated with yogurt. Acta Obstet Gynecol Scand. 72 (1993) 17-19
26. Eriksson K., Carlsson B., Forsum U., and Larsson P. A double-blind treatment study of bacterial vaginosis with normal vaginal Lactobacilli after an open treatment with vaginal clindamycin ovules. Acta Derm Venereol. 85 (2005) 42-46
27. Anukam K., Osazuwa E., Osemene G., et al. Clinical study comparing Lactobacillus GR-1 and RC-14 with metronidazole vaginal gel to treat symptomatic bacterial vaginosis. Microbes Infect. 8 (2006) 2772-2776
28. Hallén A., Jarstrand C., and Påhlson C. Treatment of bacterial vaginosis with Lactobacilli. Sex Transm Dis. 19 (1992) 146-148
29. Fredricsson B., Englund K., Weintraub L., et al. Bacterial vaginosis is not a simple ecological disorder. Gynecol Obstet Invest. 28 (1989) 156-160
30. Warren J., Abrutyn E., Hebel J., et al. for the Infectious Diseases Society of America (IDSA). Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Clin Infect Dis. 29 (1999) 745-758
31. Fihn S. Clinical practice. Acute uncomplicated urinary tract infection in women. N Engl J Med. 349 (2003) 259-266
32. Bacheller C., and Bernstein J. Urinary tract infections. Med Clin North Am. 81 (1997) 719-730
33. Foxman B. Epidemiology of urinary tract infections: Incidence, morbidity, and economic costs. Am J Med. 113 (2002) 5S-13S
34. Hooton T. Recurrent urinary tract infection in women. Int J Antimicrob Agents 17 (2001) 259-268
35. Johnson C. Definitions, classification, and clinical presentation of urinary tract infections. Med Clin North Am. 75 (1991) 241-252
36. Reid G., Bruce A., Cook R., and Llano M. Effect on urogenital flora of antibiotic therapy for urinary tract infection. Scand J Infect Dis 22 (1990) 43-47
37. Baerheim A., Larsen E., and Digranes A. Vaginal application of Lactobacilli in the prophylaxis of recurrent lower urinary tract infection in women. Scand J Prim Health Care 12 (1994) 239-243
38. Reid G., Bruce A., and Taylor M. Influence of 3-day antimicrobial therapy and Lactobacillus vaginal suppositories on recurrence of urinary tract infections. Clin Ther. 14 (1992) 11-16
39. Reid G., Bruce A., and Taylor M. Instillation of Lactobacillus and stimulation of indigenous organisms to prevent recurrence of urinary tract infections. Microecol Ther. 23 (1995) 32-45
40. Kontiokari T., Sundqvist K., Nuutinen M., et al. Randomised trial of cranberry-lingonberry juice and Lactobacillus GG drink for the prevention of urinary tract infections in women. BMJ 322 (2001) 1571
41. Borriello S., Hammes W., Holzapfel W., et al. Safety of probiotics that contain lactobacilli or bifidobacteria. Clin Infect Dis. 36 (2003) 775-880
42. Salminen M., Tynkkynen S., Rautelin H., et al. Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland. Clin Infect Dis. 35 (2002) 1155-1160
43. Boyle R., Robins-Browne R., and Tang M. Probiotic use in clinical practice: What are the risks?. Am J Clin Nutr. 83 (2006) 1256-1264
44. Cannon J., Lee T., Bolanos J., and Danziger L. Pathogenic relevance of Lactobacillus: A retrospective review of over 200 cases. Eur J Clin Microbiol Infect Dis. 24 (2005) 31-40
45. US Dept of Health and Human Services, Food and Drug Administration. 21 CFR Part 111. Current good manufacturing practice in manufacturing, packaging, labeling, or holding operations for dietary supplements. Fed Regist. 72 (2007) 34,752-34,958. http://www.fda.gov/OHRMS/DOCKETS/98fr/07-3039.pdf Accessed February 27, 2008